Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team from the University of Oxford has visualised how key cells of the immune system lock onto cancerous or infected cells to destroy them. The work was led by the Mike Dustin’s group at the Kennedy Institute of Rheumatology and experts in colorectal and ovarian cancers from across Oxford and computational biologists at the University of Birmingham.

T cell © Shutterstock

CD2 was one of the first molecules to be identified on the surface of T cells. The connection of thousands of molecules of CD2 on T cells to thousands of CD58 molecules on target cells facilitates destruction of cancerous and infected targets. The new work, published in Nature Immunology shows how the exact number of these molecular connections controls the process and how reductions of these numbers may undermine the immune response to cancer.

Dustin’s team first investigated the number of CD2 molecules on T cells controls the efficiency of T cell sensing of potential targets through a striking ‘CD2 corolla’, which they could visualize using advanced microscopy.  They then found that the T cells responsible for cancer killing had lower numbers of CD2 molecules in most colorectal and ovarian tumours that needed to be removed surgically.  The inability of the patients T cells to form the CD2 corolla in the tumour may have contributed to disease progression. 

Lead author Professor Michael Dustin, of the Kennedy Institute said: “Understanding why the potentially lifesaving T cells have low CD2 in tumours may help us understand why the immune system sometimes fails to control cancer and how we might help the patient's immune system fight cancer better by boosting CD2 expression.”

The findings also provide a framework to interpret the significance of CD2 expression in different contexts and the role it plays in disease.

The full story is available on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.